Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Breast Cancer Research and Treatment

Volumn 155, Issue 3, 2016, Pages 463-469

  Viale, Giuseppe ^a   Slaets, Leen ^b   de Snoo, Femke A ^c   Bogaerts, Jan ^b   Russo, Leila ^a   van’t Veer, Laura ^c,d   Rutgers, Emiel J T ^e   Piccart Gebhart, Martine J ^f   Stork Sloots, Lisette ^c   Dell’Orto, Patrizia ^a   Glas, Annuska M ^c   Cardoso, Fatima ^g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b EORTC DATA CENTER   (Belgium)

^c Agendia NV   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f JULES BORDET INSTITUTE   (Belgium)

^g Champalimaud Cancer Center   (Portugal)

Author keywords

Breast cancer; Concordance; ER; Gene expression; HER2; Hormone receptor; IHC FISH; PgR; TargetPrint; Tumor heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR MARKER; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA MICROARRAY; EARLY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INTRATUMORAL HETEROGENEITY; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; BIOSYNTHESIS; BREAST NEOPLASMS; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

EID: 84959089025     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3690-6     Document Type: Article

References (18)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2010
2. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007(25):5287–5312
3. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013
4. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
5. Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R et al (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15(22):7003–7011
6. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F et al (2015) The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Res 17(1):133
7. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-L et al (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26(15):2473–2481
8. Viale G, Bogaerts J, Slaets L, Rutgers E, van’t Veer L, Piccart-Gebhart MJ et al (2014) High concordance of protein (by IHC), gene (by FISH; HER2 only) and microarray readout (by TargetPrint) of ER/PR/HER2: results from the MINDACT trial. Ann Oncol 25(4):816–823
9. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van’t Veer L, Rubio IT et al (2011) The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 00:2742–2749
10. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van ‘t Veer LJ, Rubio IT et al. Baseline results of the EORTC 10041/MINDACT TRIAL (Microarray In Node 0-3 positive Disease may Avoid ChemoTherapy). ECCO 2013
11. US Food and Drug Administration. Guidance for industry and FDA staff: Statistical guidance on reporting results from studies evaluating diagnostic tests. http://medical.cms.itri.org.tw/pdf/u14.pdf Accessed 13 May 2015
12. Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37–46
13. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611–4619
14. ®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol 25(6):869–876
15. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222–5232
16. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R (2011) High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29:4279–4285
17. Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC et al (2010) Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300–4306
18. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ et al (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729–734